C3 and C4 are strongly related to adipose tissue variables and cardiovascular risk factors

European Journal of Clinical Investigation

Volumn 44, Issue 6, 2014, Pages 587-596

  Nilsson, Bo ^a   Hamad, Osama A ^a   Ahlström, Håkan ^a   Kullberg, Joel ^a   Johansson, Lars ^a   Lindhagen, Lars ^b   Haenni, Arvo ^c   Ekdahl, Kristina N ^a   Lind, Lars ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

C3; C3a desArg; C4; Cardiovascular disease; Metabolic syndrome

Indexed keywords

ANTIHYPERTENSIVE AGENT; ARGININE DERIVATIVE; C REACTIVE PROTEIN; CHOLESTEROL; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4; DESARGININE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLUCOSE; INTERCELLULAR ADHESION MOLECULE 1; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CYTOKINE; GLUCOSE BLOOD LEVEL;

ADIPOSE TISSUE; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; BODY FAT; BODY FAT DISTRIBUTION; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; LABORATORY TEST; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; STOMACH BYPASS; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; ABDOMINAL FAT; CARDIOVASCULAR DISEASES; COMPLICATION; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSIOLOGY; RISK FACTOR; WAIST HIP RATIO; WEIGHT REDUCTION;

ABDOMINAL FAT; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; COMPLEMENT C3; COMPLEMENT C4; CYTOKINES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; METABOLIC SYNDROME X; OBESITY; RISK FACTORS; WAIST-HIP RATIO; WEIGHT LOSS;

EID: 84900806689     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12275     Document Type: Article

References (32)

1. Onat A, Can G, Rezvani R, Cianflone K. Complement C3 and cleavage products in cardiometabolic risk. Clin Chim Acta 2011;412:1171-9.
2. Engstrom G, Hedblad B, Eriksson KF, Janzon L, Lindgarde F. Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes 2005;54:570-5.
3. Onat A, Hergenc G, Can G, Kaya Z, Yuksel H. Serum complement C3: a determinant of cardiometabolic risk, additive to the metabolic syndrome, in middle-aged population. Metabolism 2010;59:628-34.
4. Palikhe A, Sinisalo J, Seppanen M, Haario H, Meri S, Valtonen V et al. Serum complement C3/C4 ratio, a novel marker for recurrent cardiovascular events. Am J Cardiol 2007;99:890-5.
5. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010;11:785-97.
6. Choy LN, Rosen BS, Spiegelman BM. Adipsin and an endogenous pathway of complement from adipose cells. J Biol Chem 1992;267:12736-41.
7. Cianflone K, Xia Z, Chen LY. Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim Biophys Acta 2003;1609:127-43.
8. Persson L, Boren J, Robertson AK, Wallenius V, Hansson GK, Pekna M. Lack of complement factor C3, but not factor B, increases hyperlipidemia and atherosclerosis in apolipoprotein E-/- low-density lipoprotein receptor-/- mice. Arterioscler Thromb Vasc Biol 2004;24:1062-7.
9. Lim J, Iyer A, Suen JY, Seow V, Reid RC, Brown L et al. C5aR and C3aR antagonists each inhibit diet-induced obesity, metabolic dysfunction, and adipocyte and macrophage signaling. FASEB J 2013;27:822-31.
10. Munkonda MN, Lapointe M, Miegueu P, Roy C, Gauvreau D, Richard D et al. Recombinant acylation stimulating protein administration to C3-/- mice increases insulin resistance via adipocyte inflammatory mechanisms. PLoS ONE 2012;7:e46883.
11. Hernandez-Mijares A, Banuls C, Bellod L, Jover A, Sola E, Morillas C et al. Effect of weight loss on C3 and C4 components of complement in obese patients. Eur J Clin Invest 2012;42:503-9.
12. Halkes CJ, van Dijk H, de Jaegere PP, Plokker HW, van Der Helm Y, Erkelens DW et al. Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: effects of expanded-dose simvastatin. Arterioscler Thromb Vasc Biol 2001;21:1526-30.
13. Meijssen S, van Dijk H, Verseyden C, Erkelens DW, Cabezas MC. Delayed and exaggerated postprandial complement component 3 response in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 2002;22:811-6.
14. Engstrom G, Hedblad B, Janzon L, Lindgarde F. Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: a population-based cohort study. Eur J Cardiovasc Prev Rehabil 2007;14:392-7.
15. Lind L, Fors N, Hall J, Marttala K, Stenborg A. A comparison of three different methods to evaluate endothelium-dependent vasodilation in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Arterioscler Thromb Vasc Biol 2005;25:2368-75.
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
17. Kullberg J, von Below C, Lönn Lind, Lind L, Ahlström H, Johansson L. Practical approach for estimation of subcutaneous and visceral adipose tissue. Clin Physiol Funct Imaging 2007;27:148-53.
18. Dati F, Johnson AM, Whicher JT. The existing interim consensus reference ranges and the future approach. Clin Chem Lab Med 2001;39:1134-6.
19. Nilsson EK, Nilsson B, Pekna M, Nilsson UR. Generation of iC3 at the interface between blood and gas. Scand J Immunol 1992;35:85-91.
20. Hollman DA, Milona A, van Erpecum KJ, van Mil SW. Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms. Biochim Biophys Acta 2012;1821:1443-52.
21. Li J, Pircher PC, Schulman IG, Westin SK. Regulation of complement C3 expression by the bile acid receptor FXR. J Biol Chem 2005;280:7427-34.
22. Mazumdar B, Kim H, Meyer K, Bose SK, Di Bisceglie AM, Ray RB et al. Hepatitis C virus proteins inhibit C3 complement production. J Virol 2012;86:2221-8.
23. Gardinali M, Conciato L, Cafaro C, Crosignani A, Battezzati PM, Agostoni A et al. Complement system is not activated in primary biliary cirrhosis. Clin Immunol Immunopathol 1998;87:297-303.
24. Jones EA, Vergalla J, Steer CJ, Bradley-Moore PR, Vierling JM. Metabolism of intact and desialylated alpha 1-antitrypsin. Clin Sci Mol Med 1978;55:139-48.
25. Nilsson B, Ekdahl KN. Complement diagnostics: concepts, indications, and practical guidelines. Clin Dev Immunol 2012;2012:962702.
26. Sliwinski AJ, Zvaifler NJ. Decreased synthesis of the third component of complement (C3) in hypocomplementemic systemic lupus erythematosus. Clin Exp Immunol 1972;11:21-9.
27. Nicol PA, Lachmann PJ. The alternate pathway of complement activation. The role of C3 and its inactivator (KAF). Immunology 1973;24:259-75.
28. Mamane Y, Chung Chan C, Lavallee G, Morin N, Xu LJ, Huang J et al. The C3a anaphylatoxin receptor is a key mediator of insulin resistance and functions by modulating adipose tissue macrophage infiltration and activation. Diabetes 2009;58:2006-17.
29. Phieler J, Chung KJ, Chatzigeorgiou A, Klotzsche-von AA, Garcia-Martin R, Sprott D et al. The complement anaphylatoxin C5a receptor contributes to obese adipose tissue inflammation and insulin resistance. J Immunol 2013;191:4367-74.
30. Phieler J, Garcia-Martin R, Lambris JD, Chavakis T. The role of the complement system in metabolic organs and metabolic diseases. Semin Immunol 2013;25:47-53.
31. Samad F, Ruf W. Inflammation, obesity, and thrombosis. Blood 2013;122:3415-22.
32. Zhou X, Fukuda N, Matsuda H, Endo M, Wang X, Saito K et al. Complement 3 activates the renal renin-angiotensin system by induction of epithelial-to-mesenchymal transition of the nephrotubulus in mice. Am J Physiol Renal Physiol 2013;305:F957-67.